PI3K inhibitors in haematological malignancies

Affiliations

¹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: matasarm@mskcc.org.
² Clinical Statistics, Bayer AG, Berlin, Germany.
³ Clinical Development, Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA.
⁴ IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seragnoli," Bologna, Italy; Dipartimento di Medicina Specialistica, Diagnostica e Sperintale, Universita di Bologna, Bologna, Italy.

Comment

Matthew J Matasar et al. Lancet Oncol. 2022 Aug.

. 2022 Aug;23(8):e365.

doi: 10.1016/S1470-2045(22)00332-1.

¹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: matasarm@mskcc.org.
² Clinical Statistics, Bayer AG, Berlin, Germany.
³ Clinical Development, Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA.
⁴ IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seragnoli," Bologna, Italy; Dipartimento di Medicina Specialistica, Diagnostica e Sperintale, Universita di Bologna, Bologna, Italy.

No abstract available

Conflict of interest statement

MJM and PLZ have received support from Bayer as advisors. FH and BHC are employees of Bayer.

The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint.
Richardson NC, Kasamon Y, Pazdur R, Gormley N. Richardson NC, et al. Lancet Oncol. 2022 May;23(5):563-566. doi: 10.1016/S1470-2045(22)00200-5. Epub 2022 Apr 14. Lancet Oncol. 2022. PMID: 35429996 No abstract available.